Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Lymphoma, Non-Hodgkin
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Zevalin
Zevalin is indicated in adults. [90Y]-radiolabelled Zevalin is indicated as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. The benefit of Zevalin following rituximab in combination with chemotherapy has not been established. [90Y]-radiolabelled Zevalin is indicated for the treatment of adult patients with rituximab relapsedorrefractory CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL).
View on EMAUrinary Tract Infection
Hematoma
Parkinsons Disease (PD)
Acute Coronary Syndrome
Chronic Kidney Disease